
Ep. 195: Jim Roppel: Stock Market Lessons Of 2022
Investing With IBD
00:00
Amgen Breaks Below Its Beautiful Digestive
I think Amgen needs to be watched very carefully. biotech and semis are really the only growth areas that have any power. And it's not, you know, although we're in a short and maybe intermediate term uptrend, it's lethargic. It's mucky.
Transcript
Play full episode